News | June 03, 2022
Evonik to build new lipid production facility for mRNA-based therapies in U.S.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
By 2025, Cipla plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry.
The product will be launched by NATCO's commercial partner Viatris.
Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
This agreement is in addition to the $92 million filling line expansion announced in November 2021
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
Subscribe To Our Newsletter & Stay Updated
